Dawn I. Velligan

Dawn I. Velligan

Auto-generated profile, based on publicly available information

Dawn I. Velligan

University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
DVDawn I Velligan
Dawn I Velligan
MSMartha Sajatovic
Martha Sajatovic
AHAinslie Hatch
Ainslie Hatch
PKPavel Kramata
Pavel Kramata
JDJohn P Docherty
John P Docherty
Background: Antipsychotic medication reduces the severity of serious mental illness (SMI) and improves patient outcomes only when medicines were taken as prescribed. Nonadherence to the treatment of SMI increases the risk of relapse and hospitalization and reduces the quality of life. It is necessary to understand the factors influencing nonadherence to medication in order to identify appropriate interventions. This systematic review assessed the published evidence on modifiable reasons for nonadherence to antipsychotic medication in patients with SMI. Methods: Articles published between January 1, 2005, and September 10, 2015, were searched on MEDLINE through PubMed. Abstracts were independently screened by 2 randomly assigned authors for inclusion, and disagreement was resolved by another author. Selected full-text articles were divided among all authors for review. Results: A qualitative analysis of data from 36 articles identified 11 categories of reasons for nonadherence. Poor insight was identified as a reason for nonadherence in 55.6% (20/36) of studies, followed by substance abuse (36.1%, 13/36), a negative attitude toward medication (30.5%, 11/36), medication side effects (27.8%, 10/36), and cognitive impairments (13.4%, 7/36). A key reason directly associated with intentional nonadherence was a negative attitude toward medication, a mediator of effects of insight and therapeutic alliance. Substance abuse was the only reason consistently associated with unintentional nonadherence, regardless of type and stage of SMI. Discussion: Although adherence research is inherently biased because of numerous methodological limitations and specific reasons under investigation, reasons for nonadherence consistently identified as significant across studies likely reflect valid existing associations with important clinical implications. Conclusion: This systematic review suggests that a negative attitude toward medication and substance abuse are consistent reasons for nonadherence to antipsychotic medication among people with SMI. Adherence enhancement approaches that specifically target these reasons may improve adherence in a high-risk group. However, it is also important to identify drivers of poor adherence specific to each patient in selecting and implementing intervention strategies.

1 January 2009
Verified
Journal Article
Closed access
DVDawn I Velligan
Dawn I Velligan
PWPeter J Weiden
Peter J Weiden
MSMartha M. Sajatovic
Martha M. Sajatovic
JSJan Scott
Jan Scott
DCDaniel Carpenter
Daniel Carpenter
EIExpert Consensus Panel On Adherence Problems In Serious And Persistent Mental Illness
Expert Consensus Panel On Adherence Problems In Serious And Persistent Mental Illness

12 October 2005 in Schizophrenia Bulletin
Verified
Journal Article
Open access
PDF file
DVDawn I. Velligan
Dawn I. Velligan
YLYui-Wing Francis Lam
Yui-Wing Francis Lam
DGDavid C. Glahn
David C. Glahn
JBJennifer A. Barrett
Jennifer A. Barrett
NMNatalie J. Maples
Natalie J. Maples
AMAlexander L. Miller
Alexander L. Miller
The definition and assessment of adherence vary considerably across studies. Increasing consensus regarding these issues is necessary to improve our understanding of adherence and the development of more effective treatments. We review the adherence literature over the past 3 decades to explore the definitions and assessment of adherence to oral antipsychotics in schizophrenia patients. A total of 161 articles were identified through MEDLINE and PsycINFO searches. The most common method used to assess adherence was the report of the patient. Subjective and indirect methods including self-report, provider report, significant other report, and chart review were the only methods used to assess adherence in over 77% (124/161) of studies reviewed. Direct or objective measures including pill count, blood or urine analysis, electronic monitoring, and electronic refill records were used in less than 23% (37/161) of studies. Even in studies utilizing the same methodology to assess adherence, definitions of an adherent subject varied broadly from agreeing to take any medication to taking at least 90% of medication as prescribed. We make suggestions for consensus development, including the use of recommended terminology for different subject samples, the increased use of objective or direct measures, and the inclusion in all studies of an estimate of the percentage of medication taken as prescribed in an effort to increase comparability among studies. The suggestions are designed to advance the field with respect to both understanding predictors of adherence and developing interventions to improve adherence to oral antipsychotic medications.

1 September 2007 in Psychiatric Services
Verified
Journal Article
Closed access
DVDawn I. Velligan
Dawn I. Velligan
MWMei Wang
Mei Wang
PDPamela Diamond
Pamela Diamond
DGDavid C. Glahn
David C. Glahn
DCDesiree Castillo
Desiree Castillo
AMAlexander L. Miller
Alexander L. Miller

1 August 2000 in American Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
DVDawn I. Velligan
Dawn I. Velligan
CBC. Christine Bow-Thomas
C. Christine Bow-Thomas
CHCindy Huntzinger
Cindy Huntzinger
JRJanice Ritch
Janice Ritch
NLNatalie Ledbetter
Natalie Ledbetter
AMAlexander L. Miller
Alexander L. Miller

28 September 2005 in Schizophrenia Bulletin
Verified
Journal Article
Open access
PDF file
DVDawn I. Velligan
Dawn I. Velligan
RKRobert S. Kern
Robert S. Kern
JGJames M. Gold
James M. Gold
Cognitive rehabilitation (CR) approaches seek to enhance cognitive processes or to circumvent cognitive impairments in schizophrenia in an effort to improve functional outcome. In this review we examine the research findings on the 8 evidence-based approaches to cognitive remediation listed in the 2005 Training Grid Outlining Best Practices for Recovery and Improved Outcomes for People With Serious Mental Illness, developed by the American Psychological Association Committee for the Advancement of Professional Practice. Though the approaches vary widely in theoretical orientation and methods of intervention, the results are, for the most part, encouraging. Improvements in attention, memory, and executive functioning have been reported. However, many persons with schizophrenia are more impaired in real-world functioning than one would expect given the magnitude of their cognitive deficits. We may need to look beyond cognition to other targets such as motivation to identify the reasons that many persons with schizophrenia demonstrate such marked levels of disability. Although a number of current CR approaches address motivation to varying degrees, treating motivation as a primary target may be needed to maximize CR outcomes.